amifostine anhydrous and idarubicin

amifostine anhydrous has been researched along with idarubicin in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (84.62)	29.6817
2010's	1 (7.69)	24.3611
2020's	1 (7.69)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
de Campos Nebel, M; González-Cid, M; Larripa, I	1
Błasiak, J; Gloc, E; Majsterek, I; Młynarski, W; Skórski, T; Stolarska, M; Woźniak, K	1
Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D	1
Blasiak, J; Drzewoski, J; Gloc, E; Pertyński, T	1
Błasiak, J; Drzewoski, J; Gloc, E; Młynarski, W; Skórski, T	1
Beardell, F; Brunner, J; Capizzi, R; Cohn, J; Ferbér, A; Filicko, J; Flomenberg, N; Garcia-Manero, G; Grosso, D; Martinez, J; Mookerjee, B; Rose, L; Tice, D; Wagner, JL	1
Blasiak, J; Gloc, E; Majsterek, I; Reiter, RJ	1
Capelli, D; Discepoli, G; Leoni, P; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Troiani, E	1
Blasiak, J; Gloc, E; Morawiec, Z; Wozniak, K	1
Capelli, D; Chiarucci, M; Discepoli, G; Fiorentini, A; Leoni, P; Menotti, D; Olivieri, A; Poloni, A; Saraceni, F	1

Reviews

1 review(s) available for amifostine anhydrous and idarubicin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for amifostine anhydrous and idarubicin

Article	Year
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica, 2002, Volume: 87, Issue:8 Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome	2002
Cytoprotection in acute myelogenous leukemia (AML) therapy. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytoprotection; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis	2004

Article

Year

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.

Haematologica, 2002, Volume: 87, Issue:8

Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome

2002

Cytoprotection in acute myelogenous leukemia (AML) therapy.

Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytoprotection; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis

2004

Other Studies

10 other study(ies) available for amifostine anhydrous and idarubicin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice. Environmental and molecular mutagenesis, 2002, Volume: 39, Issue:1 Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antimutagenic Agents; Apoptosis; Blood; Bone Marrow; Comet Assay; DNA Damage; Female; Idarubicin; Liver; Male; Mice; Mice, Inbred BALB C; Micronucleus Tests; Protective Agents; Spleen; Toxicity Tests	2002
Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chemico-biological interactions, 2002, Apr-20, Volume: 140, Issue:1 Topics: Adult; Amifostine; Animals; Antibiotics, Antineoplastic; Antioxidants; Ascorbic Acid; Cell Line, Transformed; Cell Survival; Comet Assay; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Endodeoxyribonucleases; Humans; Idarubicin; Lymphocytes; Male; Mice; Mutagens; Tumor Cells, Cultured; Vitamin E; Vitamins	2002
DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine. Anti-cancer drugs, 2002, Volume: 13, Issue:10 Topics: Amifostine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Transformed; Cell Survival; Comet Assay; DNA Damage; DNA Repair; Drug Combinations; Fusion Proteins, bcr-abl; Idarubicin; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats	2002
Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia research, 2002, Volume: 26, Issue:12 Topics: Amifostine; Animals; Cell Line, Transformed; Cell Survival; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Drug Interactions; Humans; Idarubicin; Leukemia; Mice; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Tumor Cells, Cultured	2002
A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. Journal of pineal research, 2005, Volume: 38, Issue:4 Topics: Adult; Amifostine; Apoptosis; Caspase 3; Caspases; Comet Assay; DNA Damage; Electrophoresis, Gel, Pulsed-Field; HeLa Cells; Humans; Idarubicin; In Vitro Techniques; K562 Cells; Male; Melatonin	2005
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Experimental hematology, 2007, Volume: 35, Issue:7 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome	2007
Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells. Experimental oncology, 2008, Volume: 30, Issue:1 Topics: Adult; Amifostine; Antineoplastic Agents; Apoptosis; Caspase 3; DNA Breaks, Double-Stranded; DNA Fragmentation; DNA Repair; Dose-Response Relationship, Drug; Drug Interactions; Humans; Idarubicin; K562 Cells; Lymphocytes; Male; Models, Biological	2008
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment. Advances in therapy, 2020, Volume: 37, Issue:5 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Geriatric Assessment; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis	2020